In 2009, royalty income totaled € 344.9 million (2008: € 356.4 million) and mainly included royalty income from the products Avonex® (Biogen Idec), Humira® (Abbott), Enbrel® (Amgen) and Puregon® (Merck & Co.), as well as income from the active pharmaceutical ingredients bisoprolol and metformin.
In 2009, commission income totaled € 24.4 million (2008: € 31.6 million). This primarily consisted of cooperation and distribution agreements, such as for Ikorel® (Sanofi-Aventis), Euthyrox® (Bracco) and Allergan products.
back
